Drugs / MSPV4
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06011200 Comparator | Sep → Dec 2023 | meningococcal meningitis | CanSino Biologics Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSPV4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06011200 ↗ |
| Modality | Vaccine | “ACYW135 Group Meningococcal Polysaccharide Vaccine (MSPV4)” NCT06011200 ↗ |
| Route | Subcutaneous | “Subcutaneous injection, 0.5ml” NCT06011200 ↗ |